Objective: To compare the efficacy and adverse reactions of terazosin and alfuzosin in treatment of acute urinary retention in patients with benign prostatic hypertrophy. Design: Case control study. Setting: Emergency department of a regional hospital in Hong Kong. Methods: Our study included all adult male with age at least 18 years old presented with acute urinary retention, having residual urine volume greater than or equal to 300 ml after urinary catheterisation and with a presumed diagnosis of benign prostatic hypertrophy. Patients treated with terazosin from December 2013 to February 2014 were retrospectively included while patients treated with alfuzosin from April to September 2014 were prospectively included. We compared the two groups on: trial without catheter (TWOC) rate, potential adverse effects including drug-associated postural hypotension, haemodynamic changes and prolongation of corrected QT interval in electrocardiogram. Cost effectiveness analysis was performed. Results: A total of 116 patients were included with 59 and 57 patients in the terazosin and alfuzosin group respectively. Logistic regression showed that residual urine volume (odds ratio [OR]=0.998, 95% confidence interval [CI]=0.996-0.999, p=0.008) and presence of precipitating factors (OR=2.264, 95% CI=1.045-5.793, p=0.045) were independent predictors of successful TWOC. There was no significant difference in the TWOC rate for patients treated with alfuzosin and terazosin. There was significantly more symptomatic postural hypotension in the terazosin group compared with the alfuzosin group. The number need to treat with alfuzosin for terazosin to avoid one adverse drug effect was 12.3 patients (95% CI=4.7-21.6) and 9.9 patients (95% CI=5.3-84.6) to reduce one postural hypotension and symptomatic postural hypotension respectively. Conclusions: Alfuzosin is comparable to terazosin in TWOC rate. However, alfuzosin is associated with a lower rate of symptomatic postural hypotension and less haemodynamic impact than terazosin. (Hong Kong j.emerg.med. 2015;22:210-218 
Introduction
Ac ute urinar y reten tio n (AUR) is a c ommon complication of benign prostatic hypertrophy (BPH) and is a common clinical presentation in the emergency department (ED). Terazosin, the first long acting -1 b l o c k e r a p p r o v e d b y t h e F o o d a n d D r u g Administration (FDA) for treatment of symptomatic lower urinary tract symptoms (LUTS) and BPH, was commonly used at the management of AUR. However, it is not uncommon to encounter patients treated with terazosin complicated with postural hypotension, dizziness and syncope. The significant adverse effect on haemodynamic by terazosin precluded it to be a good choice of drug in ambulatory management of AUR by BPH. In recent years, number of studies [1] [2] [3] [4] had been conducted to study on alfuzosin and showed good efficacy and safety profile. However, there was no head-to-head comparison between the two drugs in the literature. It would be worthwhile to compare the profile of alfuzosin and terazosin so as to assess if alfuzosin is a wise choice of drug in outpatient management of patients with AUR due to BPH.
In this study, we aimed to compare terazosin and alfuzosin regarding their efficacy in term of successful trial without catheter (TWOC), potential adverse effects including drug-associated postural hypotension, haemodynamic changes and prolongation of corrected QT interval (QTc) as revealed by electrocardiogram (ECG). We also performed a cost effectiveness analysis for the two study drugs.
Methods

Study setting and patient inclusion
This was a case control study carried out in the ED of a regional hospital with daily attendance of over 600 patients. All adult male with age at least 18 years old presented with AUR, having residual urine volume greater than or equal to 300 ml after insertion of indwelling urinary catheter and with presumed diagnosis of BPH were included. The exclusion criteria were:
• causes of urinary retention other than BPH e.g. urethral disease or spinal cord compression • significant obstructive uropathy, by checking serum creatinine and checking patient's clinical and past medical history • active urosepsis, by checking presence of fever and evidence of urinary tract infection (UTI) by urine multistix at AED • concomitant use of potent CYP34A inhibitors like ketoconazole • moderate or severe hepatic impairment (ChildsPugh B or C cirrhosis) • hypersensitivity or allergy to alpha blockers • failure of insertion of urinary catheter in ED • known postural hypotension • on alpha blockers before the episode of urinary retention.
Data collection
Fro m December 2 0 13 t o Febr u ar y 2 0 14 , we retrospectively collected data of 59 patients treated with terazosin as the control group; while from April 2014 to September 2014, we prospectively recruited 57 patients treated with alfuzosin as the case group. For the alfuzosin group patients, once they were suspected to have urinary retention presumed to be due to BPH, prostate size in fingerbreadth and presence of fecal impaction were determined by rectal examination, then urinary catheter inserted and patients were offered bed rest for 10 minutes. Urine multistix for catheterised urine was done to detect any presence of UTI. Then the residual urine volume was defined as the urine co llec ted in u rin ar y ba g at 10 min ut es a ft er catheterisation (including the amount of the first catheterisation). Presence of gross haematuria was noted. Baseline erect and supine blood pressure (BP) was then measured and baseline ECG was done to document baseline QTc as calculated with the Bazett's formula. Alfuzosin 10 mg per oral (PO) was then given to patient while blood test of renal function test was done. Interval erect and supine BP monitoring was done at 2 hours and 4 hours after prescription of alfuzosin respectively. Any report of dizziness at these two intervals was noted. At the end of 4 hourobservation period, a second ECG was done. Patients free of dizziness with stable haemodynamics were discharged with the arrangement of urology follow up at urology clinic for TWOC 3 to 7 days after discharge (at least 3 doses of alpha blocker were taken). Patient baseline characteristics collected were listed as Table 1 . Outcome parameters recorded were listed as Table 2 . Renal impairment was defined as creatinine 109 mol according to the calibration in the local accredited laboratory, while cardiovascular disease referred to significant heart and vascular diseases except hypertension.
For the terazosin group, cases were retrieved by the electronic Clinical Data Analysis and Retrieval System searched by the diagnosis of retention of urine (ICD-9 code 788.2) under the categories of both the principal and secondary diagnoses. Eligible patients were admitted to the Emergency Medicine Ward and treated with standardised protocol.
Terazosin group medication
Terazosin 4 mg PO daily was the standard regime, while 2 mg PO daily would be given to those more than 60 years old, with significant medical co-morbidities such as cardiovascular disease. Precipitating causes such as urinary tract infection or fecal impaction were treated accordingly. As salvage procedure, physician in charge of patient might adjust (reduce) the dose of terazosin or co-existing anti-hypertensive medication if patients reported dizziness with a significant drop of BP. According to the departmental treatment guideline, most patients were discharged home after a day of observation with arrangement of urology follow up at urology clinic for TWOC few days later (or at least 3 doses of terazosin were taken). The written and electronic medical records of these 59 terazosin group patients were retrieved and reviewed, with the data collected for terazosin group patients was same as alfuzosin group.
Outcome parameters
The outcome measures were successful TWOC rate, recurrence rate of retention of urine (ROU), presence of drug-induced postural hypotension, presence of dizziness, symptomatic postural hypotension, and change of QTc interval in ECG. Successful TWOC rate was defined as successful self-voiding after tried off catheter and no retention requiring catheterisation within 3 days. Recurrence was defined as retention of urine requiring catheterisation within three months after TWOC, which was checked by retrieving electronic medical record. Postural hypotension was defined as postural drop of systolic BP of more than 20 mmHg; or a drop in diastolic BP of more than 10 mmHg measured after standing for 3 minutes. Symptomatic postural hypotension was defined as postural hypotension associated with symptom of dizziness. Significant haemodynamic changes was defined as a drop in systolic BP of more than 20 mmHg, or a drop in diastolic BP of more than 10 mmHg, or a rise in pulse rate of more than 20 beats per minute as measured at the forth hour after medication when compared to baseline. Prolonged QTc interval was defined as QTc 440 ms with the Bazett formula. To show the significant haemodynamic change of alfuzosin of 20%, with a sample of 116 (59 in terazosin group and 57 in alfuzosin group) could achieve 76% statistical power.
Results
We recruited 59 patients in terazosin group and 60 patients in alfuzosin group. The characteristics of patients were shown in Table 1 . There were significantly greater proportion of patients with precipitation factors including anticholinergic/antihistamine intake, urinary tract infection, fecal impaction in the terazosin group than in the alfuzosin group (77.6% versus 47.4%; p=0.003). Among terazosin group patients, 95% of them were prescribed either 4mg (n=37, 62.7%) or 2mg (n=19, 32.3%) regimes. Table 2 showed the univariate analysis of the outcome measures and adverse effects resulted from the study drugs. Successful TWOC rate was higher in terazosin group (n=42, 71.2%) than in alfuzosin group (n=32, 57.1%) (p=0.064). For symptomatic postural hypotension rate, terazosin group (n=7, 11.9%) was significantly higher than alfuzosin group (n=1, 1.8%) (p=0.032). There were more terazosin group patients (n=12, 20.3%) reporting dizziness than alfuzosin group patients (n=4, 7.0%) (p=0.057). Significant haemodynamic changes in 4 hours after prescription of drugs were higher in terazosin group than in alfuzosin group (89.7% versus 57.9%; p<0.001).
Boxplot of blood pressure after taken terazosin and alfuzosin was illustrated in Figure 1 . The change in both systolic and diastolic BP in Terazosin group at 2 hours and 4 hours was significantly greater than in alfuzosin group.
Variables including age, prostate size, residual urine volume, presence of hematuria, preceding LUTS, presence of precipitating factors, medication type treatment were entered into binomial logistic regression to predict for successful TWOC (Table 3 ). The good ness-o f-fit o f the logist ic regression was satisfactory with the Hosmer-Lemeshow test with p=0.962. Table 4 showed that 12.3 patients (95% CI=4.7-21.6) and 9.9 patients (95% CI=5.3-84.6) were needed to treat with alfuzosin in order to reduce one postural hypotension or one symptomatic postural hypotension respectively when compared to terazosin.
Cost-effectiveness analysis of the two study drugs was shown in Table 5 . According the Hospital Authority hospital formulary, the estimated cost for daily dose regimen were HKD$12 per month for terazosin 4mg and HKD$46.5 per month for alfuzosin 10 mg. Additional cost of HKD$424.4 (95% CI=165.6- 745.2) or HKD$341.6 (95% CI=182.9-2918.7) was required to reduce one case of postural hypotension or one case of symptomatic postural hypotension respectively.
Discussion
We demonstrated that residual urine volume, presence of precipitating factors were two significant independent predictors of successful TWOC.
Alfuzosin is known to be effective in TWOC after AUR. [1] [2] [3] [4] In our study, we did not find choice of alpha blocker (terazosin or alfuzosin) a significant i n d e p e n d e n t p r e d i c t o r o f T W O C . T h i s i s compatible with the findings of previous related studies. 6, 7 Our TWOC rate for alfuzosin (57.1%) was comparable to that of a larger scale study conducted by McNeil et al. 8 Mahadik et al 9 demonstrated strong association between age, prostate size on ultrasound and TWOC outcome. Contrary to their findings, we did not find significant association between age and prostate size in fingerbreadth with TWOC rate. Prostate size in fingerbreadth is operator dependent and has poor interrater reliability. What we found to be significant was residual urine volume which was agreed with the findings by Bhomi and Bhattachan. 10 We believe that our findings are compatible to common clinical observation that reversal of precipitating factors like constipation should help to achieve TWOC. However, for those patients presenting with great residual urine volume, they are more likely to have co-existing bladder compliance problem, 11 and therefore TWOC would be more difficult.
We demonstrated that higher proportion of patients in terazosin group was having symptomatic postural hypotension than in alfuzosin group. These results are compatible with previous studies findings. 7, 12 Terazosin has firs t-dose effect which means tha t it can cause marked lowering of BP, especially postural hypotension, in association with the first dose or first few days of therapy. In contrast, although studies of alfuzosin failed to demonstrate any receptor selectivity for the alpha-1 subtypes, 13 its slow release formulation contributes to its excellent patient tolerance without the need of dose titration. 14, 15 Extramiana et al 16 showed that there is no significant change in the QTc at therapeutic dose (10 mg) or at higher dose (40 mg) in human subjects; in our study, only small proportion of patients (5.3%) showed druginduced QTc prolongation with 10mg alfuzosin, with the greatest prolongation to be 94 ms. This was supported by the animal (rabbit) study 17 that alfuzosin could delay cardiac repolarisation by significantly increased sodium current, and thereby increasing QTc. As a result, patients with congenital or acquired prolonged QTc could be at higher risk for QT prolongation with alfuzosin administration or coadministration with medications that prolong the QT interval.
Treatment cost per month with alfuzosin is around four times of terazosin according to the current local (Hong Kong) price (Table 5 ). Use of alfuzosin apparently increases the cost of AUR treatment. However, if we take into account of hospitalisation cost of terazosin patients for monitoring of haemodynamic adverse effects, treatment with alfuzosin in out-patient basis should be a cost-effective and safe strategy. The number need to treat to avoid a case of symptomatic postural hypotension was around 10 and it is quite encouraging. The economic benefit to use alfuzosin 10 mg as initial drug in AUR patients was also supported by local and overseas groups.
18,19
Limitations
Firstly, the collection of data from the retrospective arm of the study (the terazosin group) was subjected to information bias. For example, some terazosin group patients could have underlying pre-existing postural hypotension but not documented on clinical note. Secondly, the lengths of study period of the two arms were not equal. Not all consecutive patients of eligible patients were given alfuzosin during the 3-month period because of small rate of incoherence to guideline. However, we believe that there should be no systematic selection bias. Thirdly, the treatment of terazosin group was heterogeneous with various doses. However, local study 5 demonstrated similar TWOC rate and adverse haemodynamic effects between 2 mg or 4 mg doses; and 95% of terazosin group patient in this study were receiving either 2 mg or 4 mg doses. Finally, the sample size of our study was small; a larger scale study or a randomised controlled trial study would be optimal.
Conclusions
Alfuzosin is comparable to terazosin in TWOC successful rate, with lower rate of symptomatic postural hypotension and less haemodynamic impact. Residual urine volumes, presence of precipitating factors are two significant independent predictors of successful TWOC.
